Coronavirus Disease-2019 (COVID-19): An Updated Review.


Journal

Drug research
ISSN: 2194-9387
Titre abrégé: Drug Res (Stuttg)
Pays: Germany
ID NLM: 101602406

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 4 8 2020
medline: 28 8 2020
entrez: 4 8 2020
Statut: ppublish

Résumé

The current outbreak of novel Coronavirus Disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major pandemic situation and a catastrophe for humans. COVID-19 is a severe infectious disease particularly of the respiratory system characterized by fatal complications such as severe acute respiratory distress syndrome (SARS), pneumonia, cardiac arrhythmia, kidney failure/ multiple organ failure and even death. Since its discovery, the SARS-CoV-2 has spread across 213 countries or territories, causing more than 8.5 million people with a rising death toll over 5.5 million people (as of June 2020, WHO). In fact, the current looming crisis of COVID-19 has become an increasingly serious concern to public health. It has affected lives of millions of people with severe impact on health systems and economies globally. Since there are no specific drugs and/or vaccines available so far, combating COVID-19 remains to be a major challenging task. Therefore, development of potential and effective treatment regimens (prophylactic/therapeutic) is urgently required which could resolve the issue. In this review, we summarize the current knowledge about the coronavirus, disease epidemiology, clinical manifestations and risk factors, replication of the virus, pathophysiology and host immune responses of SARS-CoV-2 infection. The therapeutic interventions and prophylactic measures along with precautionary measures are the frontline approaches that could be undertaken in order to control and prevent the spread of the deadly and highly contagious COVID-19 are also detailed herein.

Identifiants

pubmed: 32746481
doi: 10.1055/a-1217-2397
pmc: PMC7516369
doi:

Substances chimiques

Antiviral Agents 0
COVID-19 Vaccines 0
Viral Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

389-400

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Références

Cureus. 2020 Mar 21;12(3):e7355
pubmed: 32328367
Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64
pubmed: 16339739
Indian J Pharmacol. 2020 Jan-Feb;52(1):56-65
pubmed: 32201449
Lancet Rheumatol. 2020 Jul;2(7):e428-e436
pubmed: 32835246
J Proteome Res. 2020 Nov 6;19(11):4567-4575
pubmed: 32786890
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):147-159
pubmed: 32362642
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Hum Vaccin Immunother. 2020 Jun 2;16(6):1232-1238
pubmed: 32186952
Infect Dis Ther. 2020 Jun;9(2):255-274
pubmed: 32328406
Int J Mol Med. 2020 Jun;45(6):1631-1643
pubmed: 32236624
Chemotherapy. 2019;64(5-6):215-223
pubmed: 32259829
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
Struct Chem. 2020;31(5):1831-1840
pubmed: 32412544
Life Sci. 2020 Jul 1;252:117652
pubmed: 32278693
Clin Microbiol Rev. 2007 Oct;20(4):660-94
pubmed: 17934078
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
J Infect Public Health. 2020 May;13(5):667-673
pubmed: 32340833
Indian J Pediatr. 2020 Apr;87(4):281-286
pubmed: 32166607
Curr Pharmacol Rep. 2020;6(3):56-70
pubmed: 32395418
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):160-171
pubmed: 32317408
Virol J. 2019 May 27;16(1):69
pubmed: 31133031
Int J Mol Sci. 2020 Apr 18;21(8):
pubmed: 32325767
Inform Med Unlocked. 2020;19:100345
pubmed: 32395606
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5
pubmed: 32201439
Recenti Prog Med. 2020 Apr;111(4):253-256
pubmed: 32319447
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4529-4536
pubmed: 32373991
J Int AIDS Soc. 2020 Apr;23(4):e25489
pubmed: 32293807
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Natl Sci Rev. 2020 Jun;7(6):1012-1023
pubmed: 34676127
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
Cell Biosci. 2020 Mar 16;10:40
pubmed: 32190290
Int J Biol Sci. 2020 Mar 15;16(10):1753-1766
pubmed: 32226295
Int J Antimicrob Agents. 2020 Jun;55(6):105948
pubmed: 32201353

Auteurs

Mithun Rudrapal (M)

Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India.

Shubham J Khairnar (SJ)

Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India.

Laxmikant B Borse (LB)

Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India.

Anil G Jadhav (AG)

Sandip Institute of Pharmaceutical Sciences, Sandip Foundation, Nashik, Maharashtra, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH